Roger E. Susi, the CEO and founder of Iradimed Corporation (IRMD), recently executed an indirect sale of 7,500 shares of common stock over May 18 and 19, totaling approximately $657,000. This transaction, reported via SEC Form 4, aligns with Susi’s historical trading patterns, as he typically conducts around 21.6 trades annually, with sell tranches averaging between 5,000 and 10,000 shares.
This sale represents just 0.17% of Susi’s indirect holdings, leaving him with over 4.39 million shares. Notably, it occurred amid a significant rise in Iradimed’s stock price, which closed at $92.10 on May 22, reflecting an impressive one-year total return of 82.77%. The company has also reported strong financial performance, including a 13% year-over-year revenue growth in Q1, which has contributed to the stock’s appreciation.
For investors, Susi’s sale is not a cause for concern, as it was part of a pre-established Rule 10b5-1 trading plan. His continued substantial ownership suggests confidence in Iradimed’s ongoing growth trajectory.
Source: fool.com